Patents by Inventor Bruce Levine
Bruce Levine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9181526Abstract: Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4+CD25+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.Type: GrantFiled: February 6, 2012Date of Patent: November 10, 2015Assignee: The Trustees of the University of PennsylvaniaInventors: Bruce Blazar, Carl June, Wayne R. Godfrey, Richard G. Carroll, Bruce Levine, James L. Riley, Patricia Taylor
-
Patent number: 9161971Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.Type: GrantFiled: June 29, 2012Date of Patent: October 20, 2015Assignee: The Trustees of the University of PennsylvaniaInventors: Carl H. June, Bruce Levine, Anne Chew, Stephen J. Schuster
-
Patent number: 9133436Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.Type: GrantFiled: February 4, 2011Date of Patent: September 15, 2015Assignee: The Trustees of the University of PennsylvaniaInventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce Levine
-
Patent number: 8419080Abstract: A drawer safety latch that is securable, preferably releasably so, to a top surface of a drawer side structure, such as a sidewall, in one of two different orientations. The safety latch is quickly installed without modifying the drawer, is easily aligned, and can be oriented so that children shorter than the drawer cannot see the release mechanism. The drawer safety latch is preferably of one-piece, injection-molded construction, but other materials and manufacturing methods may be used. The drawer safety latch is preferably secured with releasable adhesive fabric, and so is portable for travel. In some embodiments, the drawer safety latch may have aesthetic and/or traction enhancements. The drawer safety latch has right-handed and left-handed versions that may be used alone or together, in the same or different orientations.Type: GrantFiled: February 9, 2007Date of Patent: April 16, 2013Inventor: Bruce Levine
-
Patent number: 8415150Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.Type: GrantFiled: February 24, 2010Date of Patent: April 9, 2013Assignee: The Trustees of the University of PennsylvaniaInventors: Carl H. June, Bruce Levine, Anne Chew, Stephen J. Schuster
-
Publication number: 20130071409Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.Type: ApplicationFiled: February 4, 2011Publication date: March 21, 2013Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce Levine
-
Publication number: 20120263693Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.Type: ApplicationFiled: June 29, 2012Publication date: October 18, 2012Inventors: Carl H. June, Bruce Levine, Anne Chew, Stephen J. Schuster
-
Publication number: 20120207727Abstract: Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4+CD25+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.Type: ApplicationFiled: February 6, 2012Publication date: August 16, 2012Inventors: Bruce Blazar, Carl June, Wayne R. Godfrey, Richard G. Carroll, Bruce Levine, James L. Riley, Patricia Taylor
-
Patent number: 8129185Abstract: Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4+CD25+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.Type: GrantFiled: December 29, 2009Date of Patent: March 6, 2012Assignee: The Trustees of the University of PennsylvaniaInventors: Bruce Blazar, Carl June, Wayne R. Godfrey, Richard G. Carroll, Bruce Levine, James L. Riley, Patricia Taylor
-
Publication number: 20120034249Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.Type: ApplicationFiled: February 24, 2010Publication date: February 9, 2012Inventors: Carl H. June, Bruce Levine, Anne Chew, Stephen J. Schuster
-
Patent number: 8075921Abstract: Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.Type: GrantFiled: March 30, 2010Date of Patent: December 13, 2011Assignees: The United States of America as represented by the Secretary of the Deparment of Health and Human Services, The Trustees of the University of PennsylvaniaInventors: Daniel H. Fowler, Unsu Jung, Ronald E. Gress, Bruce Levine, Carl June
-
Publication number: 20110052547Abstract: Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.Type: ApplicationFiled: March 30, 2010Publication date: March 3, 2011Applicants: Services, The Trustees of the University of PennsylvaniaInventors: Daniel H. Fowler, Unsu Jung, Ronald E. Gress, Bruce Levine, Carl June
-
Publication number: 20100291678Abstract: Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4+CD25+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.Type: ApplicationFiled: December 29, 2009Publication date: November 18, 2010Inventors: Bruce Blazar, Carl June, Wayne R. Godfrey, Richard G. Carroll, Bruce Levine, James L. Riley, Patricia Taylor
-
Patent number: 7718196Abstract: Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.Type: GrantFiled: December 9, 2005Date of Patent: May 18, 2010Assignees: The United States of America, as represented by the Department of Health and Human Services, The Trustees of the University of PennsylvaniaInventors: Daniel H. Fowler, Unsu Jung, Ronald E. Gress, Bruce Levine, Carl June
-
Patent number: 7651855Abstract: Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4+CD25+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.Type: GrantFiled: April 19, 2004Date of Patent: January 26, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: Bruce Blazar, Carl June, Wayne R. Godfrey, Richard G. Carroll, Bruce Levine, James L. Riley, Patricia Taylor
-
Publication number: 20080191496Abstract: A drawer safety latch that is securable, preferably releasably so, to a top surface of a drawer side structure, such as a sidewall, in one of two different orientations. The safety latch is quickly installed without modifying the drawer, is easily aligned, and can be oriented so that children shorter than the drawer cannot see the release mechanism. The drawer safety latch is preferably of one-piece, injection-molded construction, but other materials and manufacturing methods may be used. The drawer safety latch is preferably secured with releasable adhesive fabric, and so is portable for travel. In some embodiments, the drawer safety latch may have aesthetic and/or traction enhancements. Right-handed and left-handed versions are disclosed, and may be used alone or together, in the same or different orientations.Type: ApplicationFiled: February 9, 2007Publication date: August 14, 2008Inventor: BRUCE LEVINE
-
Publication number: 20070273830Abstract: An improved method for treating the eye includes the step of providing an ophthalmic instrument including an integral wavefront sensor. The wavefront sensor measures phase aberrations in reflections directed thereto to characterize aberrations of the eye. The wavefront sensor may be operably coupled to a display device, which displays a graphical representation of the aberrations of the eye. Such graphical representation may include: two dimensional contour maps that graphically depict contribution of pre-specified terms (such as spherical aberration, astigmatism and coma) for the aberrations of the eye, coefficients corresponding to such pre-specified terms that characterize the aberrations of the eye, or predefined two-dimensional icons that provide a general graphical depiction of such pre-specified terms.Type: ApplicationFiled: February 5, 2007Publication date: November 29, 2007Inventor: Bruce LEVINE
-
Publication number: 20060204500Abstract: The invention relates to a method for modulating HIV-1 fusion cofactor expression by manipulating CTLA-4 on the surface of T cells. The invention encompasses methods for modulating HIV-1 fusion cofactor expression by inhibiting one or more intracellular signals resulting from stimulation of CTLA-4. In one embodiment, expression of the HIV-1 fusion cofactor, CCR5, is downregulated by binding of anti-CTLA-4 antibody to CTLA-4.Type: ApplicationFiled: March 10, 2006Publication date: September 14, 2006Inventors: Carl June, Richard Carroll, James Riley, Daniel St. Louis, Bruce Levine
-
Publication number: 20060159667Abstract: Methods for generating highly enriched Th1/Tcl and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.Type: ApplicationFiled: December 9, 2005Publication date: July 20, 2006Applicants: Gov. of the US, as represented by the Secretary, Department of Health and Human Services, The Trustees of the University of PennsylvaniaInventors: Daniel Fowler, Unsu Jung, Ronald Gress, Bruce Levine, Carl June
-
Publication number: 20050196386Abstract: Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4+CD25+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.Type: ApplicationFiled: April 19, 2004Publication date: September 8, 2005Inventors: Bruce Blazar, Carl June, Wayne Godfrey, Richard Carroll, Bruce Levine, James Riley, Patricia Taylor